Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.57 |
| ▸ | JAK1 | P23458 | 8/20 | 0.57 |
| ▸ | JAK3 | P52333 | 6/20 | 0.57 |
| ▸ | TYK2 | P29597 | 6/20 | 0.57 |
| ▸ | STAT3 | P40763 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561936 | 0.89 | JAK2 (0.55) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL4561835 | 0.88 | IGF1R (0.61) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL4562555 | 0.86 | JAK2 (0.59) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL4561135 | 0.86 | JAK1 (0.60) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL22546288 | 0.85 | JAK2 (0.67) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL22545981 | 0.84 | JAK2 (0.57) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL22545979 | 0.83 | JAK1 (0.58) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL4560821 | 0.83 | AXL (0.59) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL5022297 | 0.83 | JAK1 (0.61) | JAK2JAK1JAK3TYK2STAT3 | |
| SCHEMBL4561983 | 0.83 | JAK2 (0.58) | JAK2JAK1JAK3TYK2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638018-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2013-09-18 | — | — | EP | claimed |
| WO-2012062704-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-05-18 | — | — | WO | claimed |
| CN-118702683-A | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| CN-113993861-B | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| EP-2638018-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062704-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062704-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.